CDMOs offering HPAPI Manufacturing (High-Potency) with Oligonucleotide
9 published
9 published CDMOs match HPAPI Manufacturing (High-Potency) and Oligonucleotide.
Locations in this set include United States, United Kingdom, Canada, Singapore, Asia, and China.
Capabilities that show up most often in this set: CMC Analytical Development, API Synthesis & Manufacturing, Formulation Development, Process Development, and Oligonucleotide Manufacturing.
Matching companies
Almac GroupGlobal CDMO with 7,900+ employees across 18 facilities, offering integrated drug development and manufacturing services including analytical development, formulation, process development, fill-finish, and specialized chemistry capabilities.- Asymchem LaboratoriesAsymchem is a CDMO providing integrated API synthesis, drug product development, and biologics manufacturing with specialized capabilities in peptides, oligonucleotides, highly potent compounds, and flow chemistry.
- BSP PharmaceuticalsBSP Pharmaceuticals is a CDMO specializing in development and manufacturing of cytotoxic oncology drugs, ADCs, peptides, proteins, and lipid-based formulations from preclinical GLP through commercial supply.
BioVectraNorth American CDMO specializing in clinical-to-commercial biologics, small molecules, HPAPIs, and bioreagents with 50+ years of microbial fermentation and complex chemistry expertise across cGMP facilities in Canada.
CordenPharmaFull-service CDMO offering cGMP development and manufacturing of APIs, lipid excipients, drug products, injectables, peptides, LNPs, oligonucleotides, and oral solid dose across 10 facilities in 6 countries with 3000+ employees.
Dalton Pharma ServicesHealth Canada–approved and FDA-inspected cGMP contract manufacturer offering integrated drug discovery, development, and manufacturing services including custom synthesis, API production, formulation development, and sterile fill-finish for vials, syringes, and cartridges.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
VeranovaGlobal CDMO specializing in development and manufacturing of complex active pharmaceutical ingredients (APIs), with expertise in solid form sciences, process development, and specialty modalities including ADCs and controlled substances.
Markdown mirror: /explore/hpapi-manufacturing/oligonucleotide.md